It seems that generic pharmaceuticals are around two-thirds of MYX's sales. Price erosion in the generic market allegedly because of consolidation of buyers/distributors has brought revenues down, although less than in the previous period.
Can anyone offer an insight into what extent price erosion might continue? Of course, if prices start to slide closer to the cost of production, MYX's generic lines can become unviable. I imagine that in a scenario of further price squeezes the Indian pharmaceutical manufacturers would have an advantage of lower production costs, is that a fair assumption? Do the Indian companies exhibit higher margins at the moment because of their (assumed) lower production costs?
The threat of price erosion?
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.50 |
Change
-0.120(2.60%) |
Mkt cap ! $382.8M | |||
| Open | High | Low | Value | Volume |
| $4.60 | $4.62 | $4.47 | $280.2K | 61.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 126 | $4.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.52 | 538 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| MYX (ASX) Chart |